STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESYLATE, DOSAGE FORMS THEREOF AND METHODS FOR USING THEM

STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESYLATE, DOSAGE FORMS THEREOF AND METHODS FOR USING THEM

Farmaceutski sastav naznačen time da se sastoji od učinkovite količine aktivnog sastojka koji čini bifeprunoks mesilat i najmanje jednog farmaceutski prihvatljivog ekscipijenta, - pri čemu barem oko 90% masenih aktivnog sastojka je kristalni polimorfni oblik α (alfa), a manje od 10% masenih čine δ (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HENDRIKUS T. RIGTER, CAROLINE BOON, ERIC GOUT, KLAAS ZWIER, GERRIT KLEIN, NICO BRUINS, MICHIEL H. DE VRIES, MARIA J.I. TERHORST-VAN AMSTEL, IRENE EIJGENDAAL
Format: Patent
Sprache:hrv ; eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Farmaceutski sastav naznačen time da se sastoji od učinkovite količine aktivnog sastojka koji čini bifeprunoks mesilat i najmanje jednog farmaceutski prihvatljivog ekscipijenta, - pri čemu barem oko 90% masenih aktivnog sastojka je kristalni polimorfni oblik α (alfa), a manje od 10% masenih čine δ (delta) ili γ (gama) oblici, sa karakteristikama difrakcije x-zraka na prahu navedenih oblika kako slijedi: The present disclosure provides novel pharmaceutical compounds and methods for making the same, novel pharmaceutical dosage forms and methods for making the same, and methods for using said compounds and dosage forms to treat and prevent diseases and/or disorders.